AJAnnie Jeffery

Annie Jeffery

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Annie Jeffery has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A consensus diabetes core dataset for research using NHS data: outputs from a Diabetes Data Science Catalyst workshop

    by Katherine G Young, Amitava Banerjee, Colin Dayan, Spiros Denaxas, Sophie V Eastwood, Annie Jeffery, Martin K Rutter, Naveed Sattar, Jonathan Valabhji, Richard Horswood, et al.

    Aims: To develop a ‘core’ dataset of diabetes related variables to support reproducible research using UK routinely collected health data. Methods: A workshop was conducted bringing together diabetes healthcare professionals, researchers, and patient and public representatives to discuss and prioritise variables for inclusion in the Diabetes Core Dataset. Core variables were those considered to be highest priority for diabetes research and available at high quality in NHS data routinely used for research (primary care [GP] and Hospital Episode Statistics [HES] data). Candidate variables for inclusion in the Diabetes Core Dataset were from a review of existing core datasets and expert opinion. Participants scored variables anonymously based on priority for diabetes research. Results: 25 variables from existing diabetes core datasets and 87 other candidate variables were considered for inclusion in the Diabetes Core Dataset. All 25 of those from existing diabetes core datasets and 5 of the 87 candidate variables met the core requirements for inclusion. In addition, 7 variables were identified as high priority but not included in the core dataset as they are not currently available in GP/HES data; these were labelled as ‘future high priority’ variables for diabetes research. Conclusions: A new diabetes core dataset for UK EHR research has been developed using a consensus-based process. The core dataset is openly available and can be flexibly applied in UK EHR ( https://healthdatagateway.org/en/tool/426 ), including in new NHS Research Secure Data Environment platforms, to enhance reproducible research to improve the clinical care of people with diabetes and associated conditions.

  • Open Access

    Impact of 15 years of social, political and economic shocks on population mental health in the UK: a longitudinal, Bayesian quasi-experimental analysis

    by Annie Jeffery, Connor Gascoigne, Ioannis Rotous, Xuewen Yu, Sara Geneletti, Gianluca Baio, Marta Blangiardo, James B Kirkbride

    Background: Mental health in the UK has worsened over the last 15 years, a period marked by major systemic shocks. Objective: We investigated annual changes in population-level psychological distress and the impact of five systemic shocks: the referendum on European Union membership (Brexit), two COVID-19 lockdowns, Russia’s invasion of Ukraine and the UK Government’s 2022 ‘mini-budget’. Methods: We used longitudinal survey data from the UK Household Longitudinal Study, including 87 857 between years 2009 and 2024. We used Bayesian time series models to evaluate annual changes in psychological distress and the association with each shock, including subgroup analyses by age group, sex, ethnicity, deprivation quintile and employment status. Outcomes: We found evidence of increasing psychological distress from 2009 to 2023 (+1.085 point increase in 12-item General Health Questionnaire scores; credible interval (CrI) 0.987 to 1.184). In interrupted time series models, we observed increased psychological distress immediately after the Brexit referendum (+0.117, CrI 0.029 to 0.205) and the first COVID-19 lockdown (+0.649; CrI 0.531 to 0.767), with more insidious monthly increases in psychological distress after the Russian invasion of Ukraine (+0.010, CrI 0.004 to 0.023) and the 2022 mini-budget (+0.015, CrI 0.005 to 0.034). We found considerable sociodemographic variation by age, sex, ethnicity, deprivation and employment status. Conclusions: We found that some systemic shocks had detrimental effects on population mental health in the UK, being most pronounced for the Brexit referendum and first COVID-19 lockdown. Clinical implications: Our results demonstrate that population mental health can change in response to systemic shocks. This should inform the design of responsive clinical and public mental health provision.

  • Open Access

    Antidepressant prescribing inequalities in people with comorbid depression and type 2 diabetes: A UK primary care electronic health record study

    by Yutung Ng, Joseph F Hayes, Annie Jeffery

    Aims: To compare the likelihood of being prescribed an antidepressant in depressed individuals with and without type 2 diabetes. Methods: We performed a matched cohort study using primary care record data from the UK Clinical Practice Research Datalink. We used multivariable logistic regression to compare antidepressant prescribing during the first five years of starting oral antidiabetic medication to a comparison group without type 2 diabetes, matched based on GP practice, age and sex. We performed subgroup analyses stratified by sex, age and ethnicity. Results: People with type 2 diabetes and depression were 75% less likely to be prescribed an antidepressant compared to people with depression alone (odds ratio (OR) 0.25, 95% confidence interval (CI) 0.25 to 0.26). This difference was greater in males (OR 0.23, 95% CI, 0.22 to 0.24), people older than 56 years (OR 0.23, 95% CI, 0.22 to 0.24), or from a minoritised ethnic background (Asian OR 0.14, 95% CI 0.12–0.14; Black OR 0.12, 95% CI 0.09–0.14). Conclusions: There may be inequalities in access to antidepressant treatment for people with type 2 diabetes, particularly those who are male, older or from minoritised ethnic backgrounds.

  • Open Access

    Mortality and hospital admissions in people with eating disorders. A longitudinal cohort study in secondary-care linked English primary care records.

    by Annie Jeffery, Joseph Hayes, Naomi Launders, Glyn Lewis, David Osborn, Helen Bould, Naomi Warne, Francesca Solmi

    Background. Research on mortality and admissions for physical health problems across eating disorder diagnoses in representative settings is scarce but necessary to understand clinical needs of this population. Inequalities in these health outcomes across a range of socio-demographic characteristics have rarely been investigated.Aims. We investigated whether people with eating disorders had greater all-cause mortality and physical health-related admissions compared to people without eating disorders and whether associations varied by sex, ethnicity, deprivation, age, and calendar year at diagnosis.Methods. Using primary care Clinical Research Practice Datalink linked to Hospital Episode Statistics, we matched people with an incident eating disorder diagnosis (any, anorexia nervosa, bulimia nervosa, EDNOS, generic eating disorders, or a referral code) to four people without eating disorders. We used univariable and multivariable Cox (mortality) and Poisson (admissions) models and fitted interactions to investigate whether associations varied by socio-demographic characteristics. Results. We included 58,735 people (90.1% female, 91.6% white). People with eating disorders had higher all-cause mortality (Hazard Ratio[HR]: 2.15, 95% confidence interval [CI]: 1.73 – 2.67). Anorexia nervosa had the highest mortality (HR: 3.49, 95%CI: 2.43 – 5.01). People with any eating disorders had higher rates of planned (Incidence Rate Ratio[IRR]: 1.44, 95%CI: 1.40 – 1.47), emergency (IRR: 1.67. 95%CI: 1.62 – 1.72) and emergency admissions for injuries, accidents and substance misuse (IRR: 2.18, 95%CI: 2.06 – 2.31). Mortality rate ratios were greater in males, and admission rate ratios in males, older people, and people living in affluent areas of England. Conclusions. People with eating disorders have high rates of mortality and admissions. We observed inequalities in outcomes across specific socio-demographic groups, calling for an understanding of why such inequalities exist. These findings highlight the need for prompt and effective treatment for eating disorders and for improved guidance on primary care management of people with eating disorders.

  • Open Access

    Antidepressant prescribing inequalities in people with comorbid depression and type 2 diabetes: a UK primary care electronic health record study

    by Y Ng, J Hayes, A Jeffery

    Aims To compare the likelihood of being prescribed an antidepressant in depressed individuals with and without type 2 diabetes. Methods We performed a matched cohort study using primary care record data from the UK Clinical Practice Research Datalink. We used multivariable logistic regression to compare antidepressant prescribing during the first five years of starting oral antidiabetic medication to a comparison group without type 2 diabetes, matched based on GP practice, age and sex. We performed subgroup analyses stratified by sex, age and ethnicity. Results People with type 2 diabetes and depression were 75% less likely to be prescribed an antidepressant compared to people with depression alone (odds ratio (OR) 0.25, 95% confidence interval (CI) 0.25 to 0.26). This difference was greater in males (OR 0.23, 95% CI, 0.22 to 0.24), people older than 56 years (OR 0.23, 95% CI, 0.22 to 0.24), or from a minoritised ethnic background (Asian OR 0.14, 95% CI 0.12-0.14; Black OR 0.12, 95% CI 0.09-0.14). Conclusions There may be inequalities in access to antidepressant treatment for people with type 2 diabetes, particularly those who are male, older or from minoritised ethnic backgrounds.

  • Open Access

    Antidepressant treatment and mortality in people with comorbid depression and type 2 diabetes: UK electronic health record study

    by Annie Jeffery, Kate Walters, Ian C. K. Wong, David Osborn, Joseph F. Hayes

    Background: Depression is associated with higher rates of premature mortality in people with physical comorbidities, such as type 2 diabetes. Conceptually, the successful treatment of depression in people with type 2 diabetes could prevent premature mortality.Aims: To investigate the association between antidepressant prescribing and the rates of all-cause and cause-specific (endocrine, cardiovascular, respiratory, cancer, unnatural) mortality in individuals with comorbid depression and type 2 diabetes.Method: Using UK primary care records between years 2000 and 2018, we completed a nested case–control study in a cohort of people with comorbid depression and type 2 diabetes who were starting oral antidiabetic treatment for the first time. We used incident density sampling to identify cases who died and matched controls who remained alive after the same number of days observation. We estimated incidence rate ratios for the association between antidepressant prescribing and mortality, adjusting for demographic characteristics, comorbidities, medication use and health behaviours.Results: We included 5222 cases with a recorded date of death, and 18 675 controls, observed for a median of 7 years. Increased rates of all-cause mortality were associated with any antidepressant prescribing during the observation period (incidence rate ratio 2.77, 95% CI 2.48–3.10). These results were consistent across all causes of mortality that we investigated.Conclusions: Antidepressant prescribing was highly associated with higher rates of mortality. However, we suspect that this is not a direct causal effect, but that antidepressant treatment is a marker of more severe and unsuccessfully treated depression.


  • Open Access

    The effect of immigration policy reform on mental health in people from minoritised ethnic groups in England: an interrupted time series analysis of longitudinal data from the UK Household Longitudinal Study cohort

    by Annie Jeffery, Connor Gascoigne, Jennifer Dykxhoorn, Marta Blangiardo, Sara Geneletti, Gianluca Baio, James B Kirkbride


  • Open Access

    Association between polypharmacy and depression relapse in individuals with comorbid depression and type 2 diabetes: a UK electronic health record study

    by Annie Jeffery, Cini Bhanu, Kate Walters, Ian C. K. Wong, David Osborn, Joseph F. Hayes

    Individuals with physical comorbidities and polypharmacy may be at higher risk of depression relapse, however, they are not included in the ‘high risk of relapse’ group for whom longer antidepressant treatment durations are recommended. In individuals with comorbid depression and type 2 diabetes (T2DM), we aimed to investigate the association and interaction between depression relapse and (a) polypharmacy, (b) previous duration of antidepressant treatment. This was a cohort study using primary care data from the UK Clinical Practice Research Datalink (CPRD) from years 2000 to 2018. We used Cox regression models with penalised B-splines to describe the association between restarting antidepressants and our two exposures. We identified 48 001 individuals with comorbid depression and T2DM, who started and discontinued antidepressant treatment during follow-up. Within 1 year of antidepressant discontinuation, 35% of participants restarted treatment indicating depression relapse. As polypharmacy increased, the rate of restarting antidepressants increased until a maximum of 18 concurrent medications, where individuals were more than twice as likely to restart antidepressants (hazard ratio (HR) = 2.15, 95% CI 1.32–3.51). As the duration of previous antidepressant treatment increased, the rate of restarting antidepressants increased – individuals with a previous duration of ≥25 months were more than twice as likely to restart antidepressants than those who previously discontinued in <7 months (HR = 2.36, 95% CI 2.25–2.48). We found no interaction between polypharmacy and previous antidepressant duration. Polypharmacy and longer durations of previous antidepressant treatment may be associated with depression relapse following the discontinuation of antidepressant treatment.


  • Open Access

    Polypharmacy and antidepressant acceptability in comorbid depression and type 2 diabetes: a cohort study using UK primary care data

    by Annie Jeffery, Cini Bhanu, Kate Walters, Ian Ck Wong, David Osborn, Joseph F Hayes

    Background: Polypharmacy may increase the risk of drug interactions, side effects, and poor adherence; however, the impact of polypharmacy on antidepressant acceptability in individuals with type 2 diabetes (T2DM) is unknown.Aim: To investigate the association between number of prescribed medications and early antidepressant discontinuation in adults with T2DM.Design and setting: Cohort study using UK primary care data from the Clinical Practice Research Datalink between 1 January 2000 and 31 December 2018.Method: Cox regression with penalised B-splines was used to describe the association between the number of concurrently prescribed medications at the time of starting antidepressant treatment and each of the outcomes.Results: A total of 73 808 individuals with comorbid depression and T2DM starting antidepressant treatment for the first time were identified. A median of 7 concurrent medications were prescribed. Within 32 weeks, 44.26% (n= 32 665) of participants discontinued antidepressant treatment altogether, and 11.75% (n= 8672) of participants switched antidepressant agents. An inverse relationship between the number of concurrent medications and discontinuing antidepressant treatment altogether was found. The median of 7 concurrent medications was associated with a 65.06% decrease in early antidepressant discontinuation; hazard ratio 0.45, 95% confidence interval = 0.37 to 0.55. No evidence of an association between the number of concurrent medications and switching antidepressant agents was found.Conclusion: Early discontinuation of antidepressants is common in adults with T2DM; however, individuals with higher levels of concurrent polypharmacy may be more adherent to treatment. These are likely to represent individuals with worse physical or mental health. Individuals with lower levels of concurrent polypharmacy may benefit from adherence support.